Tejnaksh Healthcare Limited Reviews Q2 After 47% FY26 Profit Fall

Tejnaksh Healthcare Limited will consider its unaudited Q2 FY27 standalone and consolidated results on November 12, 2026, after its FY26 consolidated net profit fell 47.4% to ₹1.18 crore and revenue from operations declined 16.3% to ₹10.79 crore.

When will Tejnaksh Healthcare Limited announce Q2 FY27 results?

Tejnaksh Healthcare Limited has scheduled a board meeting for November 12, 2026, to consider and approve its unaudited standalone and consolidated financial results for the July-September quarter of FY27. The company disclosed the meeting date through its regulatory communication, placing it among more than 350 listed companies scheduled to report quarterly earnings on the same day.

The meeting is significant because it will provide the next formal update on the company's operating and financial performance after the audited FY26 results. No Q2 FY27 revenue, profit, margin or earnings-per-share figure was available in the provided disclosures before the board's consideration of the results.

The company also noted the closure of its trading window in connection with the results process. Such restrictions apply to designated persons, including directors and employees covered by the company's insider-trading code, until the results are released and the stipulated period has elapsed.

Some supplied market updates refer to the November 12 meeting as being held for Q3 results. However, the company-specific board-meeting information states that the meeting will consider unaudited Q2 standalone and consolidated results. The quarterly period identified for Q2 FY27 is July to September 2026.

What was Tejnaksh Healthcare Limited's FY26 financial performance?

Tejnaksh Healthcare Limited reported consolidated net profit of ₹1.18 crore for the year ended March 31, 2026, down 47.4% from ₹2.23 crore in FY25. Revenue from operations declined 16.3% to ₹10.79 crore from ₹12.90 crore a year earlier, according to the audited annual results approved by the board.

Total income for FY26 stood at ₹11.18 crore, compared with ₹13.30 crore in FY25. Total expenses were ₹9.53 crore, lower than ₹10.11 crore in the preceding year. Despite the reduction in expenses, the fall in revenue resulted in a lower annual profit.

For the March 2026 quarter, consolidated profit was ₹0.35 crore, compared with ₹0.42 crore in the corresponding quarter of the previous year. FY26 earnings per share were ₹0.61, against ₹1.15 in FY25.

The statutory auditors, M/s Maheshwari and Co, issued an unmodified opinion on the annual financial results. The consolidated accounts include the performance of Tejvedaant Healthcare Private Limited, the company's subsidiary.

How did recent quarterly profitability change?

Tejnaksh Healthcare Limited's reported quarterly data shows net profit of ₹0.29 crore for the June 2026 quarter, compared with ₹0.50 crore in the March 2026 quarter and ₹0.34 crore in the June 2025 quarter. The June 2026 figure was lower sequentially but higher than the comparable year-ago quarter in the data table.

Sales in the June 2026 quarterly table were ₹1.84 crore, compared with ₹1.77 crore in March 2026 and ₹1.78 crore in June 2025. Operating profit was ₹0.70 crore, versus ₹0.81 crore in the March 2026 quarter and ₹0.74 crore in the June 2025 quarter.

Operating profit margin for the June 2026 quarter was 38.04%, down from 45.76% in March 2026 and 41.57% in June 2025. Depreciation remained at ₹0.33 crore in each of these three quarters, while interest expense was ₹0.01 crore in June and March 2026, compared with ₹0.04 crore in June 2025.

The Q2 FY27 announcement will therefore be watched for evidence on revenue movement, operating margin and profit after the reported June-quarter performance. The available information does not provide management guidance or analyst estimates for the September quarter.

Why did Tejnaksh Healthcare Limited withdraw its rights issue plan?

Tejnaksh Healthcare Limited decided in May 2026 not to proceed with a previously proposed rights issue because its expansion plans had been postponed. The decision was taken alongside the approval of audited standalone and consolidated FY26 results.

A rights issue would have allowed the company to offer additional shares to existing shareholders, subject to the relevant terms and approvals. By cancelling the proposal, the board indicated that it would not pursue that route at the time, given the postponement of the linked expansion plans.

The annual-results disclosure also said the board re-appointed M/s Kapil Tulsani & Associates as internal auditor for the period from April 1, 2026, to March 31, 2027. These governance actions are separate from the operating numbers but provide context for the company's FY27 reporting cycle.

For investors, the deferred expansion plan remains relevant because it affects the previously stated reason for raising equity capital. The supplied information does not specify a revised expansion timetable, project size or alternative funding arrangement.

What could investors assess in the November 12 results?

Investors can assess whether Tejnaksh Healthcare Limited's Q2 FY27 figures show a change in revenue, expenses, operating profitability and net profit from the levels reported in FY26 and the June 2026 quarter. The board meeting itself does not establish the direction of those metrics because the September-quarter financial statements had not been disclosed in the supplied material.

The FY26 results showed that revenue declined more sharply than expenses, which was followed by a substantially lower annual profit. The June 2026 quarterly table also showed a sequential decline in both operating profit and net profit versus March 2026. These reported figures make the next release relevant for tracking whether the company has sustained, improved or weakened those financial measures.

The stock-market response, if any, will depend on the published results and disclosures rather than the meeting notice alone. The trading-window closure is a procedural measure under the company's compliance framework and should not be read as an indication of financial performance.

The November 2 disclosure concerning Managing Director Dr. Ashish V. Rawandale-Patil's selection as a mentor for the Endourological Society's Technology Innovation Program 2027 did not contain financial data. It is therefore separate from the quarterly earnings assessment.

Conclusion

Tejnaksh Healthcare Limited's November 12 board meeting will deliver its next reported financial update following an FY26 in which consolidated revenue fell to ₹10.79 crore and net profit declined to ₹1.18 crore. The company's latest disclosed financial context includes lower profit in the March 2026 quarter and a lower operating margin in the June 2026 quarterly table.

Investors will next watch for the unaudited Q2 FY27 standalone and consolidated results, including revenue, operating margin, net profit and any board commentary on the postponed expansion plans. The supplied disclosures do not state a revised plan for the cancelled rights issue or a new expansion schedule.